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ABSTRACT: Background: The cellular prion protein
(PrPC) is a membrane-bound, multifunctional protein mainly
expressed in neuronal tissues. Recent studies indicate that
the native trafficking of PrPC can be misused to internalize
misfolded amyloid beta and α-synuclein (aSyn) oligomers.
Objectives: We define PrPC’s role in internalizing misfolded
aSyn in α-synucleinopathies and identify further involved
proteins.
Methods: We performed comprehensive behavioral studies
on four transgenic mousemodels (ThySyn and ThySynPrP00,
TgM83 and TgMPrP00) at different ages. We developed
PrPC-(over)-expressing cell models (cell line and primary corti-
cal neurons), used confocal laser microscopy to perform
colocalization studies, applied mass spectrometry to identify
interactomes, and determined disassociation constants using
surface plasmon resonance (SPR) spectroscopy.
Results: Behavioral deficits (memory, anxiety, locomotion,
etc.), reduced lifespans, and higher oligomeric aSyn levels
were observed in PrPC-expressing mice (ThySyn and
TgM83), but not in homologous Prnp ablated mice
(ThySynPrP00 and TgMPrP00). PrPC colocalized with and
facilitated aSyn (oligomeric and monomeric) internalization in
our cell-based models. Glimepiride treatment of PrPC-
overexpressing cells reduced aSyn internalization in a dose-
dependent manner. SPR analysis showed that the binding
affinity of PrPC to monomeric aSyn was lower than to oligo-
meric aSyn. Mass spectrometry-based proteomic studies
identified clathrin in the immunoprecipitates of PrPC and
aSyn. SPR was used to show that clathrin binds to recombi-
nant PrP, but not aSyn. Experimental disruption of clathrin-
coated vesicles significantly decreased aSyn internalization.
Conclusion: PrPC’s native trafficking can be misused to
internalize misfolded aSyn through a clathrin-based mecha-
nism, whichmay facilitate the spreading of pathological aSyn.
Disruption of aSyn-PrPC binding is, therefore, an appealing
therapeutic target in α-synucleinopathies. © 2021 The
Authors.Movement Disorders published by Wiley Periodicals
LLC on behalf of International Parkinson and Movement Dis-
order Society
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Lewy bodies (LB) are diagnostic hallmarks of certain
α-synucleinopathies, including Parkinson’s disease
(PD) and dementia with Lewy bodies.1-3 LBs are com-
posed of α-synuclein (aSyn) aggregates, other proteins,
lipids, and membranes.4 aSyn has multiple physiological
functions in synaptic biology.2,5 aSyn can also misfold and
accumulate, resulting in α-synucleinopathies, diseases char-
acterized by subcortical multisystem degeneration with
neuronal loss and gliosis.6 Oligomerized aSyn (OL-aSyn)
is cytotoxic in cell-based systems.7 α-Synucleinopathies are
thought to be caused by the internalization and accumula-
tion of soluble OL-aSyn.8,9
The pathological propagation of α-synucleinopathies is
consistent with a prion-like propagation. The pathogenic
aSyn template induces the intracellular conversion of
native aSyn into the pathogenic form, thereby amplifying
the pathogenic conformation. The internalization of the
pathogenic conformation facilitates its spread from neu-
ron to neuron.10-14 This internalization of extracellular
aSyn has been proposed to occur by several different
mechanisms.15 OL-aSyn are internalized by endocytosis,
implying a selective uptake mechanism.16
The cellular prion protein (PrPC) is highly conserved
and transiently resides on the surface of neurons and
other tissues before it is internalized.17 It has previously
been shown to protect stressed cells.18-20 PrPC can be
induced to refold into an infectious conformation
(prion protein scrapie; PrPSc), which is internalized by a
PrPC-mediated mechanism to cause transmissible
spongiform encephalopathies.21,22 Previous studies
posit that the native PrPC internalization may also
be misused to internalize other prion-like protein
refolding diseases, such as amyloidopathies and α-
synucleinopathies.23-25 This hypothesis is supported by
recent studies showing that PrPC may facilitate the
internalization of extracellular amyloid beta oligomers.
Once internalized, these amyloid beta oligomers may be
amplified intracellularly and influence disease progres-
sion by contributing to different cellular dysfunc-
tions.26-28 A similar mechanism of internalization has
also been proposed for intercellular transfer of
misfolded aSyn.25 We recently demonstrated that OL-
aSyn-induced long-term potentiation (LTP) hippocam-
pal deficits25 are mediated by PrPC, suggesting it has a
role in α-synucleinopathies.29
We bred four different lines of mice, each with or
without Prnp ablated and exhibiting a rapid or slowly
developing aSyn pathology. We developed two trans-
genic cell models, one that natively expresses low levels
of PrPC and the other that overexpresses PrPC. These
models were used to elucidate PrPC’s role in α-
synucleinopathies. In addition, we used mass spectrom-
etry to define the interactome of PrPC and aSyn. Surface
plasmon resonance (SPR) was used to determine the
binding constants of PrPC with monomeric-aSyn
(mono-aSyn) and OL-aSyn.
Material and Methods
Behavioral Testing of Mice
Behavioral tests (Supplemental Material S1) were per-
formed according to previously described protocols.30
To avoid potential influence of sex, we used male mice
in our behavior studies.
Cell Culture
Human neuroblastoma cell line SH-SY5Y (SHWT)
was maintained in Dulbecco’s modified Eagle medium
(Biochrom, Berlin, Germany) containing 10%
fetal bovine serum, 1% penicillin/streptomycin, 1%
L-glutamine at 37C, 5% CO2, and 95% humidity. A
previously described transfection procedure was used to
generate a cell line that permanently overexpressed
PrPC.31
Preparation of Primary Cortical Neurons
Cells were prepared with some modification
according to a previously published protocol (Supple-
mental Material S1).20,32
Cell Treatment with aSyn
SHWT cells were plated onto six-well plates to
approximately 90% confluence. The treatment
occurred according to the following protocol (Supple-
mental Material S1).
Fractionation
Cells and mouse brain homogenates were partitioned
into cytosolic, membrane, nuclear, and cytoskeletal
fractions using the Qproteome Cell Compartment Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions (Supplemental Material S1).
Western Blot Analyses
Western blot was performed using previously
described protocols (Supplemental Material S1).30,33
Colocalization Studies by Confocal Laser
Microscopy
Colocalization studies used fluorescent dye-labeled
antibodies and nucleic acid staining dyes to determine
the locations of PrPC, aSyn, and the nucleus. Anti-PrPC
mouse monoclonal (PrP specific antibody, scrapie asso-
ciated fibrils, SAF32) and anti-aSyn rabbit monoclonal
(MJFR1) antibodies (0.5 μg/mL) facilitated colocaliza-
tion analysis (Supplemental Material S1).
Determination of Total-aSyn and OL-aSyn by
Enzyme-Linked Immunosorbent Assay
The measurement of total-aSyn and OL-aSyn
was determined by enzyme-linked immunosorbent
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assay (ELISA; Euroimmun/ADx, Gent, Belgium) follow-
ing the manufacturer’s instructions (Supplemental
Material S1).
Co-Immunoprecipitation
The monoclonal anti-aSyn (MJFR1; Abcam, Cam-
bridge, UK) and anti-PrPC (SAF32; Bertin Bioreagent,
Hamburg, Germany) antibodies were bound to mag-
netic Dynabeads according to the manufacturer’s
instructions (Supplemental Material S1).
Production of Recombinant Human PrPC
Full-length recombinant human PrPC (rHuPrP)
expression was induced by the Overnight Express Auto-
induction System 1 (Catalog No. 71300-4; Novagen,
Madison, WI), according to the manufacturer’s instruc-
tions (Supplemental Material S1).
Statistical Analysis
All data analytic results are representative of three
independent experiments. Data were evaluated using
GraphPad Prism 6.01 statistical software (GraphPad
Software, San Diego, CA; Supplemental Material S1).
1.12 Ethics Approval
The study has been approved by the Lower Saxony
State Office for Consumer Protection and Food Safety
(No. 16/2073).
Results
PrPC Knockout Partly Rescues Deficits in
ThySyn and TgM83 Mice Accompanied with
Higher OL-aSyn Levels and a Changed Cellular
Localization of aSyn
We created two transgenic mouse lines to study
PrPC’s role in α-synucleinopathies. The first line
(ThySynPrP00) was a cross between a more rapidly
progressive α-synucleinopathy phenotype (ThySyn)34
and a Prnp ablated (PrP00) mouse line (Zurich 1).35
The second mouse line (TgMPrP00) was a cross
between a line exhibiting a familial PD mutation
(TgM83) displaying a mild-progressive phenotype with
PrP00 mice. In addition, we used a wild-type (WT)
mouse line (C57BL/6J) and a PrP00 (C57BL/6J) mouse
line. These animals and their tissues were used in our
experiments to assess the effect of ablating PrPC expres-
sion on aSyn-associated phenotypes (Supplemental
Material S1).
To determine if Prnp ablation altered native aSyn
expression, different forms of aSyn were measured in
the brains of our transgenic mice. ELISA-based mea-
surement showed no significant differences in total-
aSyn levels. However, OL-aSyn levels were significantly
lower in ThySynPrP00 compared with ThySyn mice
(Fig. 1 A1,A2) and in TgMPrP00 compared with
TgM83 mice (Fig. S1A1,A2). Three phosphorylated
analogs of aSyn (p-aSyn) (phosphorylation at serine
87, tyrosine 125, and serine 129 [p87, p125, and
p129]) were assayed by Western blots of the cerebral
cortex from the four transgenic mouse lines (ThySyn,
ThySynPrP00, TgM83, TgMPrP00). In 9-month-old
ThySyn and ThySynPrP00 mice, the levels of the three
different phosphorylated forms of aSyn were not signifi-
cantly different (Fig. 1B). Analogous experiments were
performed on TgM83 and TgMPrP00 mice and compa-
rable results (Fig. S1B) were observed, suggesting that
ablating Prnp does not influence the endogenous aSyn
or p-aSyn levels.
We wanted to determine the subcellular locations of
PrPC and aSyn in the cerebral cortex. Samples were par-
titioned into four cellular fractions (cytosol, membrane,
cell nucleus, and cytoskeleton). Housekeeping proteins
(glyceraldehyde-3-phosphate-dehydrogenase [GAPDH],
histone 3, and Na+-K+-adenosine triphosphatase
(ATPase)) were used as loading controls for the differ-
ent cellular fractions (Fig. 1C–F). aSyn levels were
higher in the cytosolic fraction of ThySynPrP00 mice
compared with ThySyn mice (Fig. 1C); in the mem-
brane fraction, they tended to be higher without signifi-
cance (Fig. 1D). The total expression levels and the
subcellular localization of PrPC were not significantly
changed (only a tendency of lower PrPC levels in the
membrane) in ThySyn and TgM83 mice compared with
WT mice (Fig. S2A–F). A subcellular colocalization
with aSyn could be observed in the cytosol (Figs. 1C–F
and S2B-F).
Ablation of PrPC Extends the Life Span of aSyn
Transgenic Mice
The lifespans of ThySynPrP00 versus ThySyn
mice and TgMPrP00 versus TgM83 mice were deter-
mined. Others have shown that the lifespan of PrP00
and WT mice are comparable, indicating that Prnp
ablation does not affect a mouse’s lifespan.35 We
observed that the lifespan of the ThySynPrP00
mouse line was significantly longer (P < 0.01) than that
of the ThySyn line (Fig. 2A). Analogously, the lifespan
of the Prnp-ablated TgMPrP00 (n = 33) mouse line
was significantly longer (P < 0.05) than that of the
PrPC-expressing TgM83 (n = 31) mouse line (Fig.
S1C). Together, these data indicate that ablation of
Prnp can moderate aSyn-associated reductions in
lifespan.
Prnp Knockout Reduces Behavioral Deficits
Related to Misfolded aSyn In Vivo
We monitored Prnp ablation’s role in moderating
behavioral deficits, induced by an aSyn pathology, by
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FIG. 1. Legend on next page.
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comparing ThySyn with WT mice and ThySynPrP00
with PrP00 mice. We previously showed that older (9–
24 months) PrP00 mice show behavioral changes.30,36
We used six behavioral tests to analyze the influence of
Prnp ablation in transgenic mice: nest building (adap-
tive behavior), open field (locomotor activity), novel
object recognition (memory), elevated plus maze (EPM;
anxiety), fear conditioning (associative learning), and
rotarod (motoric skills). The first comparison (ThySyn
with WT) revealed significant differences in locomotor
behavior, associative learning, cognition, and anxiety
levels after 9 months. Interestingly, ablation of Prnp in
ThySynPrP00 mice partly rescued the behavioral abnor-
malities in locomotor activity, anxiety, associative
learning (context and tone dependent), and memory
performance, which occurred in ThySyn mice
(Fig. 2B–F). We did not observe deficits in the rotarod
task with either ThySyn or WT mice. The observed def-
icits in nesting and locomotor activity in the ThySyn,
but not WT, mice suggests moderate motoric dysfunc-
tions in ThySyn mice (Fig. 2B,H,I).
A second mouse line, TgM83, exhibits a moderate
aSyn pathology phenotype that permitted the investiga-
tion of behavioral differences at older ages. Behaviors
were compared between TgM83 and WT mice and
between TgMPrP00 and PrP00 mice at ages 9 and
18 months. TgM83 mice demonstrated greater basal
anxiety levels than the WT mice, starting at 9 months
and increasing by 18 months (Fig. S1D). No significant
difference in basal anxiety levels could be detected
between TgMPrP00 and PrP00 mice at the ages. In
addition, nest-building deficits in TgM83 compared
with WT mice were observed in 18-month-old mice
(Fig. S1E), whereas the rotarod test performance
remained unchanged (Fig. S1F).
PrPC Promotes aSyn Internalization In Vitro
We used the human neuronal cell lines, SH-SY5Y
with PrPC over expression (SHPrP) and SH-SY5Y
(SHWT) to study the influence of PrPC levels on the
uptake of aSyn. The SHWT cell line natively expresses
extreme low levels of PrPC. The SHPrP line was
engineered to overexpress levels of PrPC (approximately
fourfold) than the SHWT line (Fig. S3A,B). Each cell
line was incubated for 12 hours with a nontoxic con-
centration (1 μM) of either added recombinant mono-
aSyn or OL-aSyn (Fig. 3A2,B2). Incubation with 1 μM
of mono-aSyn was sufficient to detect a significant dif-
ference in uptake (without toxicity).37 Transmission
electron microscopy (TEM) analysis of mono-aSyn and
OL-aSyn showed that the monomeric solution con-
tained no aSyn aggregates or fibrils, whereas the aggre-
gated aSyn fraction contained a mixture of oligomeric
and fibrillary aSyn species (Fig. 3A2,B2). Western blot
signals of internalized mono-aSyn and OL-aSyn were
quantified by densitometry. Our data indicated that
SHPrP cells incubated with mono-aSyn had a signifi-
cantly higher increase (≈1.5-fold) in levels of intracellu-
lar mono-aSyn compared with similarly treated SHWT
cells (Fig. 3A1–3). Cells treated with OL-aSyn showed
higher amounts of internalized OL-aSyn
(an approximately fourfold change) in SHPrP than in
SHWT cells (Fig. 3B1-3). These results are consistent
with a PrPC-dependent internalization of OL-aSyn.
Subsequently, we quantified the amount of
phosphorylated-aSyn (p-129aSyn [p129]) after both cell
lines (SHPrP, SHWT) were treated either with mono-
aSyn or OL-aSyn. Treatment of SHPrP or SHWT cells
with mono-aSyn yielded nonphosphorylated internal-
ized aSyn (Fig. S4A, B). Treating SHWT cells with OL-
aSyn yielded a similar result. However, when SHPrP
cells were treated with OL-aSyn, a significant increase
of internalized p129 aSyn was observed (Fig. S4A,B).
These results are consistent with a PrPC-dependent
internalization of OL-aSyn followed by phosphoryla-
tion by endogenous kinases.
We performed a series of aSyn (human) uptake
experiments using cortical neurons derived from WT
and PrP00 mice. TEM analysis of the OL-aSyn or
mono-aSyn fraction showed that the OL-aSyn also con-
tained soluble aSyn fibrils, whereas the mono-aSyn did
not (Fig. S5A2,B2). Primary cortical neuronal cells were
isolated and then cultivated for 7 days to allow process
formation. They were incubated with nontoxic
amounts (1 μM) of mono-aSyn and OL-aSyn. Western
blot data were quantified by densitometry, which rev-
ealed that WT-derived cells incorporate significantly
FIG. 1. Detection of different forms of aSyn and their subcellular distribution in ThySyn and ThySynPrP00 mice. Enzyme-linked immunosorbent assay
measurement showing equal total-aSyn levels and a higher amount of soluble recombinant aSyn fraction consisting of oligomers and small fibrils (OL-
aSyn) in ThySyn compared with ThySynPrP00 mice (A1, A2). Western blots showing p-aSyn (p125 and p129) levels and a graphical summary of those
data. aSyn and p-aSyn (p125 and p129) levels are similar in 9-month-old ThySyn and ThySynPrP00 mice (B). Brain homogenates were separated into
four fractions (cytosol, membrane, cell nucleus, and cytoskeleton). In ThySynPrP00 mice, aSyn levels were detected by Western blot. Percentages of
aSyn levels in each fraction were calculated in relation to total amounts of aSyn in all fractions (only indicated for cytosol and membrane). ThySynPrP00
mice indicated a higher amount of aSyn in the cytosolic fraction compared with ThySyn mice. GAPDH, histone 3, and Na+-K+-adenosine
triphosphatase (ATPase) represent specific loading controls for different cellular compartments (C–F). Data are presented as mean  standard deviation
(n = 8 per experimental group). The two groups were compared using the Wilcoxon Mann–Whitney test. The number of asterisks indicates the signifi-
cance level: *P < 0.05. aSyn, α-synuclein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; OL-aSyn, oligomeric-aSyn; p-aSyn, phosphorylated
analogs of aSyn.
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more mono-aSyn and OL-aSyn by an approximately
fourfold or 60-fold change compared with the
Prnp00-derived cells (Fig. S5A1,A3,B1,B3). Again,
these results are consistent with a PrPC-dependent inter-
nalization of aSyn.
Glimepiride treatment induces the cleavage of the protein
portion of PrPC from the surface of cells, such as SHPrP
cells that overexpress it.38 Before aSyn treatment, SHPrP
cells were incubated with varying concentrations
(0–50 μM) of glimepiride for 2 hours. After incubation,
FIG. 2. PrPC facilitates aSyn-induced toxicity as indicated by decreased survival times and observed behavioral deficits at 9 months. The lifespan of
ThySyn mice (n = 28) is significantly reduced (341 days; 95% CI  0.4292 to 1.507) compared with ThySynPrP00 (n = 28; 424 days; 95% CI  0.6636
to 2.330) mice (P < 0.01; Mantel Cox test, Gehan-Breslow-Wilcoxon test) (A). Locomotor activity (measured by grid crossings in the open field test) was
decreased in ThySyn mice compared with WT mice, but not in ThySynPrP00 compared with PrP00 mice (B). Context-dependent and tone-dependent
associative learning (measured by the fear conditioning test) was decreased in ThySyn mice compared with WT mice, but not in ThySynPrP00 and
PrP00 mice (C,D). Cognitive performance and curiosity were measured by the novel object recognition test. Mean duration of exploration of the novel
object in relation to the familiar one was reduced in ThySyn mice compared with WT mice but not in ThySynPrP00 mice compared with PrP00 mice
(E). ThySyn mice exhibited a decline in basal anxiety compared with WT mice, as shown by the significantly greater time spent in open arms in the
EPM. ThySynPrP00 mice showed no significant differences compared with PrP00 mice (F). No significant differences could be detected within the two
sets of mouse lines in terms of the total distance traveled in the open field or the rotarod test (time spent on the rod) (G,H). Nesting was significantly
decreased in ThySyn mice compared with WT mice after 9 months (I). The two groups (WT vs. ThySyn and PrP00 vs. ThySynPrP00) were compared
using the Wilcoxon Mann–Whitney test. The number of asterisks indicates the significance level: *P < 0.05, **P < 0.01 and ***P < 0.001. Values are
depicted as mean  standard deviation. N = 12 per experimental group. aSyn, α-synuclein; CI, confidence interval; EPM, elevated plus maze; FC, fear
conditioning; NOR, novel object recognition; OF, open filed; PrPC, cellular prion protein; PrP00, Prnp knockout; WT, wild-type. [Color figure can be
viewed at wileyonlinelibrary.com]
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cellular proteins were analyzed by Western blot. The inten-
sities of the PrPC bands were quantified by densitometry
(Fig. 3C1–2). These data indicate that reducing the amount
of natively expressed PrPC on a cell’s surface results in a
lower amount of internalized aSyn (Fig. 3C1–4).
Based on a Pearson correlation analysis, the amounts of
FIG. 3. Legend on next page.
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expressed PrPC and intracellular aSyn were correlated
(Fig. 3C5). This suggests that (glycosylphosphatidylinositol
[GPI] anchor-bound) PrPC is required for the internalization
of extracellular aSyn.
PrPC and aSyn Colocalize in the Cytosol
In Vitro
Four subcellular fractions of SHPrP and SHWT cells
were isolated to determine the extent of PrPC and aSyn
colocation in each fraction. After incubating SHPrP and
SHWT cells with mono-aSyn for 12 hours, the cells
were washed, homogenized, and separated into four
distinct fractions. Each fraction was analyzed by West-
ern blot. PrPC is found in comparable amounts in both
the membrane and cytosol fractions. Both PrPC and
aSyn were found colocalized in the cytosolic fractions
of SHWT and SHPrP cells. Higher levels of both PrPC
and internalized aSyn were found in SHPrP than in
SHWT cells (Fig. 4A–D).
Colocalization and Interaction of PrPC With
aSyn in SHPrP Cells
The locations of PrPC and aSyn were visualized by
immunocytochemistry. The images (green) show, as
expected, that SHPrP cells expressed higher levels of
PrPC than SHWT cells (Fig. S6A,B). The images (total-
aSyn in red) display higher signal intensities when incu-
bated with OL-aSyn, particularly in SHPrP cells. The
overlap of the aSyn and PrPC signals is a measure of
colocalization that was quantified by calculating the
Manders’ overlap coefficient. Based on this analysis,
SHPrP cells treated with OL-aSyn showed a signifi-
cantly higher colocalization coefficient compared with
SHPrP treated with mono-aSyn or SHWT cells treated
with mono-aSyn or OL-Syn (Fig. S6C).
FIG. 3. Cellular internalization of aSyn is facilitated by PrPC. SHWT and SHPrP cells were treated for 12 hours with recombinant mono-aSyn and
OL-aSyn (1 μM). After 12 hours, the levels of internalized mono-aSyn (15 kDa) and OL-aSyn (37 kDa) were readily detected by Western blot in treated
cells, whereas untreated cells showed barely detectable amounts of endogenous aSyn (A1, B1). Transmission electron microscope images of recombi-
nant mono-aSyn and OL-aSyn solutions show the absence and presence of fibrils, respectively (A2, B2). Graphs of the densitometric quantification
aSyn uptake in SHWT and SHPrP cells (A3, B3). SHPrP cells were treated with glimepiride (GL) (1–50 μM) for 2 hours and then incubated for 12 hours
with OL-aSyn. GL treatment results in the cleavage of PrPC’s GPI anchor, releasing it from the plasma membrane and into the medium. With increasing
concentrations of GL, a smaller amount of membrane-bound PrPC was detected (C1, C2). Densitometric quantification showed a gradual dose-
dependent decrease of internalized OL-aSyn as the concentration of GL is increased (accompanied by a decrease in PrPC) (C3, C4). A P value <0.001
is considered as extremely significant (***), <0.01 very significant (**), <0.05 significant (*), and ≥0.05 not significant (ns). aSyn, α-synuclein;
DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GL, glimepiride; GPI, glycosylphosphatidylinositol; mono-aSyn,
monomeric-aSyn; OL-aSyn, oligomeric-aSyn; PrPC, cellular prion protein; SHPrP, SH-SY5Y with PrPC over expression; SHWT, SH-SY5Y wild-type
PrPC; WT, wild-type.
FIG. 4. Cellular localization of PrPC and aSyn. Detection of PrPC and aSyn in one of the four subcellular fractions (cytosol, membrane, cell nucleus, and
cytoskeleton) from SHWT and SHPrP cells after a 12-hour treatment with aSyn (1 μM). In SHPrP cells, aSyn and PrPC were mainly colocalized in the
cytosol fraction that is barely visible in SHWT cells (A, B). All protein bands between 37 kDa and 25 kDa represent different glycoforms or truncated
forms of PrPC. The main glycoforms are di-, mono- and un-glycosylated PrPC between 29 and 37 kDa (A–D). GAPDH, histone 3, and Na+-K+-ATPase
represent specific loading controls for different cellular compartments. aSyn, α-synuclein; ATPase, adenosine triphosphatase; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase; PrPC, cellular prion protein; SHPrP, SH-SY5Y with PrPC over expression; SHWT, SH-SY5Y wild-type PrPC.
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Common Interaction Partners of PrPC and aSyn
Cortical brain homogenates from ThySyn mice were
immunoprecipitated using Dynabeads coupled with
either a PrPC-specific (SAF32 [mouse]) or an aSyn-
specific (MJFR1 [rabbit]) monoclonal antibody.
Dynabeads incubated with nonspecific mouse or rabbit
immunoglobulin G showed no signals (data not
shown). Western blot–based analysis showed the pres-
ence of both PrPC and aSyn in the brain homogenate
prior to immunoprecipitation (Fig. S7A1–3). PrPC
(29–36 kDa) and aSyn (15 kDa) were present in both
immunoprecipitates (Fig. S7A1–3), confirming an
in vivo PrPC–aSyn interaction.
Co-immunoprecipitates (co-IPs) were analyzed via
qualitative mass spectrometry to define the interactome
of PrPC and aSyn. This allows a precise characterization
of PrPC and aSyn-binding partners with the goal of
identifying other proteins that may be involved in PrPC-
mediated aSyn uptake. A total of 131 proteins were
identified in the PrPC co-IP. For the aSyn co-IP,
FIG. 5. Clathrin is a mediator of PrPC-facilitated internalization of extracellular aSyn. When SH-SY5Y with PrPC overexpression (SHPrP) cells were
treated with a clathrin inhibitor Pitstop 2 (Pitstop) the expressed levels of clathrin remained unchanged; enzyme-linked immunosorbent assay–based
analysis showed that significantly less total-aSyn and OL-aSyn was internalized (A). Western blot analysis showed comparable amounts of expressed
clathrin in WT and PrP00 mice, indicating that Prnp ablation does not perturb clathrin protein expression levels (B). ThySyn mice showed a significantly
higher level of expressed clathrin compared with ThySynPrP00 mice (C). A P value <0.001 is considered as extremely significant (***), <0.01 very signifi-
cant (**), <0.05 significant (*), and ≥0.05 not significant (ns). aSyn, α-synuclein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; OL-aSyn,
oligomeric-aSyn; PrPC, cellular prion protein; SHPrP, SH-SY5Y with PrPC over expression; SHWT, SH-SY5Y wild-type PrPC; WT, wild-type.
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42 proteins were identified by mass spectrometry. Of
these 173 proteins, 38 were common to both co-IPs
(Fig. S7B; Tables S1–S3). The Uniprot (https://www.
uniprot.org/) database was used to identify their known
or purported physiological function. Most are involved
in protein binding and catalytic processes (Fig. S7C).
Of the 38 common interaction partners, we noticed that
clathrin had the highest spectral count value
(Tables S1–S3), suggesting that it might be involved in
the PrPC-mediated internalization of aSyn. Clathrin
forms the triskelia that create cage-like lattices that
facilitate classical endocytosis via clathrin-coated pits.39
Inactivation of Clathrin-Coated Vesicles
Reduces the Uptake of aSyn via PrPC
The drug Pitstop 2 disrupts the formation of clathrin-
coated vesicles.40 We used it to evaluate clathrin’s role in
the PrPC-mediated uptake of aSyn. Treatment of SHPrP
cells with Pitstop 2 did not change the levels of expressed
clathrin. SHPrP cells were treated with Pitstop 2 and
incubated with OL-aSyn. ELISA-based analysis of intra-
cellular (total and OL) aSyn revealed that Pitstop
2–treated cells contained less intracellular aSyn com-
pared with untreated SHPrP cells (Fig. 5A1-4). Western
blot was used to quantify the expressed levels of clathrin
in ThySyn versus ThySynPrP00 mice and WT versus
PrP00 mice. ThySynPrP00 mice showed significantly less
clathrin protein than ThySyn mice. In contrast, WT and
PrP00 mice expressed similar levels of clathrin,
suggesting clathrin partners in the PrPC-mediated inter-
nalization of aSyn (Fig. 5B1–2 and C1-2).
SPR Studies of rHuPrP, OL-aSyn, and Clathrin
Binding
SPR was used to measure the binding of mono-aSyn
and OL-aSyn to recombinant human PrPC (rHuPrP).
Interestingly, we found a direct protein–protein interaction
between rHuPrP (ligand) and aSyn (analyte; mono and
OL; Fig. S8A,B). In contrast, recombinant chimeric-ham-
ster-sheep PrP (negative control) failed to bind aSyn (Fig.
S8C). Anti-PrPC mAb-12F10 was used as a positive con-
trol (Fig. S8D). In addition, we observed a direct interac-
tion between rHuPrP and clathrin, but not between
clathrin and OL-aSyn (Fig. S8E, F). SPR data were used to
calculate the binding constants for rHuPrP to mono-aSyn,
OL-aSyn, or clathrin. The 1:1 Langmuir model was
applied to mono-aSyn binding41 and the bivalent analyte
model for OL-aSyn binding because OL-aSyn may exhibit
more than one binding site. The equilibrium constant (KD)
value of mono-aSyn (KD = 3.70E-09) was higher than the
KD values of OL-aSyn (KD = 2.39E-09), indicating a
higher binding affinity of rHuPrP to OL-aSyn (Fig. S8A,
B). The SPR-based KD for the rHuPrP–clathrin interaction
was found to be 2.34E-10 (Fig. S8E).
Discussion
Various experimental models have shown that PrPC
has a role in internalizing the β-sheet rich forms of
amyloid beta and tau, thereby facilitating their spread
among cells.29,42-44 This implies an interaction and a
colocalization of PrPC with those misfolded amyloid
proteins.26,45-47 Researchers showed the important
role PrPC has in aSyn internalization.29 Ablating Prnp
in cortical neurons rescues them from OL-aSyn-
induced inhibition of LTP.25 Others reported that
OL-aSyn does not bind PrPC nor does it have a role in
α-synucleinopathies.48 The evidence for PrPC’s role in
internalizing aSyn is, therefore, contradictory and
needs to be resolved.
To clarify the role of PrPC in facilitating the cell-to-
cell spread of α-synucleinopathies, we created two
Prnp-ablated transgenic mouse lines with different aSyn
pathologies. The first line displayed a more rapidly pro-
gressive phenotype (ThySyn).34,35 The second mouse
line displayed a milder phenotype and contained a
familial PD mutation (TgM83). Both Prnp-ablated lines
exhibited an increase in lifespan compared with the
PrPC-expressing progenitor ThySyn or TgM83 lines.
After 9 months, behavioral deficits in locomotor activ-
ity, nest building, memory function, and associative
learning and a decrease in basal anxiety were observed
in ThySyn mice, but not in the ThySynPrP00 mice. In
TgMPrP00 mice, the rescue of aSyn-induced behavioral
deficits was partially confirmed. aSyn-related motoric
deficits, not detected by the rotarod test, were con-
firmed by other behavioral tests such as nesting and
open field performance. These inconsistent results may
be a consequence of different test protocols and more
sensitive motor tests such as wire hanging, nesting, and
gnawing being used.49 The total expressed levels of
aSyn and p-aSyn were not significantly different in
ThySyn versus ThySynPrP00 or TgM83 versus
TgMPrP00 mice. We observed a significant decrease in
OL-aSyn as well as a change in the subcellular localiza-
tion of aSyn after PrP knockout in mice expressing
mutated aSyn. These observations support the hypothe-
sis that PrPC facilitates the internalization of misfolded
aSyn, resulting in aSyn-mediated toxicity. Furthermore,
the PrPC-mediated internalization of extracellular
misfolded aSyn is an important mechanism for the
spread of α-synucleinopathies among cells.11,12,50,51
We showed that PrPC preferentially favors internaliz-
ing OL-aSyn (an approximately fourfold change) over
mono-aSyn (≈1.5-fold change). Our results confirm
those of other researchers who demonstrated that PrPC
internalizes soluble misfolded aSyn. Prnp ablation has
been shown to partly rescue cells from the functional
impairment of LTP.29 This implies an important role
for PrPC in the internalization of aSyn required for
intercellular spread of α-synucleinopathies.
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Treatment of PrPC-expressing cells with glimepiride
cleaves the protein portion of PrPC from the cell sur-
face. We observed a dose-dependent decrease in aSyn
levels after treating SHPrP cells with glimepiride. This
supports the hypothesis that PrPC’s native membrane
trafficking is important for aSyn internalization.
These results were further confirmed by the PrPC-
mediated uptake of OL-aSyn in primary cortical neu-
rons from WT mice when compared with analogous
cells from PrP00 mice. These cell-based results show
the dependence of aSyn internalization on the pres-
ence and expression levels of PrPC.
Cellular fractionation and immunocytochemical
costaining showed that aSyn and PrPC are colocalized.
In PrPC-overexpressing (SHPrP) cells, comparable
amounts of PrPC are found in the membrane and cyto-
sol fractions, while subtantial amounts of aSyn were
detected in the cytosol of these cells. These data support
the hypothesis that aSyn internalization is facilitated by
PrPC. We used the ThySyn mouse line and a co-IP to
demonstrate an interaction between aSyn and PrPC
in vivo, which was consistent with previous studies.25,29
Our work also demonstrated that, after incubation
with either mono-aSyn or OL-aSyn, PrPC colocalized
with internalized aSyn. Previous work, using several
anti-PrPC antibodies raised against different epitopes on
PrPC, showed that amino acids 93 to 109 of PrPC are
involved in the binding with aSyn.25,29
Our SPR experiments employed recombinant human
PrPC to show direct PrP-aSyn binding. Other researchers
isolated native murine PrPC for their SPR-based aSyn-
binding studies. They were unable to show binding, a cru-
cial element for the receptor hypothesis.48 This lack of bind-
ing may be due to the improper folding of the glycosylated
and GPI anchor-containing PrPC protein, use of an inappro-
priate capture antibody, use of aSyn from brain homoge-
nates, and other differences in experimental protocol. By
using immobilized purified recombinant prion protein (rPrP)
(the same secondary and tertiary structure as PrPC; no GPI
anchor or glycosylation), we showed a direct interaction of
rPrP with both forms of aSyn. The equilibrium dissociation
constants (KD) of the rPrP/mono-aSyn and or rPrP/OL-aSyn
complex were determined to be 3.70E-09 and 2.39E-09,
respectively, indicating a higher binding affinity of PrPC to
OL-aSyn.
Previously, we proposed that aSyn and PrPC may
form a complex that induces metabotropic glutamate
receptor 5 to phosphorylate Fyn kinase.25 This interac-
tion suggested a possible link to clathrin. We used qual-
itative mass spectrometry to determine the interactome
of the co-IPs of aSyn and PrPC. Clathrin was the pro-
tein with the highest number of spectral counts that
was common to both co-IPs. Interestingly, clathrin
forms triskelia that build clathrin-coated vesicles that
facilitate endocytosis.52 For this reason, it was chosen
for further analysis.
Our other SPR results showed a direct interaction
between PrPC and clathrin. Because the SPR data
related to aSyn and clathrin binding do not correspond
to co-IP findings, we conclude that aSyn may be indi-
rectly attached to clathrin via PrPC. Our other data
indicate that levels of clathrin protein are significantly
lower in ThyPrP00 compared with ThySyn mice.
Expressed clathrin levels are comparable in WT and
PrP00 mice, so simple Prnp ablation is not responsible
for this observed reduction. Other researchers showed
that PrPC is initially localized in lipid rafts. When PrPC
binds copper, its conformation is distorted, which
allows copper-bound PrPC to migrate from the lipid raft
to the detergent soluble portion of the plasma mem-
brane, where it can be endocytosed via clathrin-coated
pits.53 We showed that Pitstop 2–treated SHPrP cells
show a significant dose-dependent reduction of aSyn
internalization. Because Pitstop 2 is an inhibitor of vesi-
cle formation, this implies that clathrin-mediated endo-
cytosis is involved in aSyn internalization. Other work
on mesenchymal stem cells showed a protective effect
of blocking clathrin-mediated endocytosis of extracellu-
lar aSyn, which aligns with our findings.54 We suggest
that binding of OL-aSyn to PrPC induces a conforma-
tional change that permits this complex to migrate from
the lipid raft region into detergent soluble regions of
the cell membrane. Once in the detergent soluble
region, OL-aSyn-bound PrPC can be internalized by
clathrin-coated vesicles (Fig. S9).
This work provides evidence for one possible uptake
mechanism. Alternative mechanisms to internalize
misfolded aSyn are possible, including tunneling nan-
otubes or exosome release.55,56 In the future we plan to
confirm the PrPC-clathrin-mediated internalization
using in vivo models and translational studies. We also
plan to quantify the relative contribution of PrPC-
mediated aSyn internalization and intercellular spread
on disease progression.
In conclusion, our data provide in vivo and in vitro
evidence supporting a molecular mechanism for the
PrPC-mediated internalization of aSyn. This mechanism
is a plausible explanation for the observed OL-aSyn-
induced phenotypes in two different mouse models.
Furthermore, our work highlights potential therapeutic
targets (PrPC, clathrin) to impede aSyn internalization.
A disruption could prevent the intercellular movement
of OL-aSyn and, therefore, potentially prevent or slow
the progression of α-synucleinopathies.
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